Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model

Prostaglandins and Other Lipid Mediators

Volumn 104-105, Issue , 2013, Pages 42-48

  Chen, Lingdan ^a   Fan, Cheng ^a   Zhang, Yi ^a   Bakri, Mahinur ^b   Dong, Hua ^c   Morisseau, Christophe ^c   Maddipati, Krishna Rao ^d   Luo, Pengcheng ^e,f   Wang, Cong Yi ^a   Hammock, Bruce D ^c   Wang, Mong Heng ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HUBEI POLYTECHNIC UNIVERSITY   (China)

^f Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention   (China)

Author keywords

Apoptosis; CYP derived eicosanoids; Glucose homeostasis; Islets

Indexed keywords

CYTOCHROME P450 2C; EPOXIDE HYDROLASE; GLUCOSE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ATTENUATION; CELL ISOLATION; CONFERENCE PAPER; CONTROLLED STUDY; FLUID INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INHIBITION KINETICS; INSULIN TOLERANCE TEST; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NICK END LABELING; NONHUMAN; ORGAN WEIGHT; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PANCREAS WEIGHT; SPLEEN WEIGHT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; APOPTOSIS; BENZOATES; DIABETES MELLITUS, EXPERIMENTAL; DRINKING; ENZYME INHIBITORS; EPOXIDE HYDROLASES; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; ISLETS OF LANGERHANS; MALE; MICE; ORGAN SIZE; OXIDATIVE STRESS; PANCREAS; SPLEEN; STREPTOZOCIN; UREA;

EID: 84879694969     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2012.12.001     Document Type: Conference Paper

References (31)

1. J.W. Yoon, and H.S. Jun Autoimmune destruction of pancreatic beta cells Am J Ther 12 2005 580 591
2. M. Cnop, N. Welsh, J.C. Jonas, A. Jörns, S. Lenzen, and D.L. Eizirik Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities Diabetes 54 2005 S97 S107 (Pubitemid 43343337)
3. P. Luo, and M.H. Wang Eicosanoids, beta-cell function, and diabetes Prostaglandins Other Lipid Mediat 95 2011 1 10
4. G. Boden Obesity, insulin resistance and free fatty acids Curr Opin Endocrinol Diabetes Obes 18 2011 129 143
5. K. Eckardt, A. Taube, and J. Eckel Obesity-associated insulin resistance in skeletal muscle: role of lipid accumulation and physical inactivity Rev Endocr Metab Disord 12 2011 163 172
6. X. Zhao, and J.D. Imig Kidney CYP450 enzymes: biological actions beyond drug metabolism Curr Drug Metab 4 2003 73 84 (Pubitemid 36131685)
7. J.D. Imig Eicosanoids and renal vascular function in diseases Clin Sci 111 2006 21 34 (Pubitemid 44023408)
8. J.D. Imig Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases Am J Physiol 289 2005 F496 F503 (Pubitemid 41208461)
9. Y. Deng, K.N. Theken, and C.R. Lee Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation J Mol Cell Cardiol 48 2010 331 341
10. J.D. Imig, and B.D. Hammock Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nat Rev Drug Discov 8 2009 794 805
11. J.D. Imig Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors Cardiovasc Drug Rev 24 2006 169 188 (Pubitemid 46696923)
12. P. Luo, H.H. Chang, Y. Zhou, S. Zhang, S.H. Hwang, and C. Morisseau Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis J Pharmacol Exp Ther 334 2010 430 438
13. A. Luria, A. Bettaieb, Y. Xi, G.J. Shieh, H.C. Liu, and H. Inoue Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance Proc Natl Acad Sci USA 108 2011 9038 9043
14. K.R. Maddipati, and S.L. Zhou Stability and analysis of eicosanoids and docosanoids in tissue culture media Prostaglandins Other Lipid Mediat 94 2011 59 72
15. J.Y. Liu, H.J. Tsai, S.H. Hwang, P.D. Jones, C. Morisseau, and B.D. Hammock Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation Br J Pharmacol 156 2009 284 296
16. 2 in the islets J Biol Chem 281 2006 29330 29336 (Pubitemid 44507076)
17. C.Y. Zhang, G. Baffy, P. Perret, S. Krauss, O. Peroni, and D. Grujic Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes Cell 105 2001 745 755 (Pubitemid 32635104)
18. Y. Zhou, H. Huang, H.H. Chang, J. Du, J.F. Wu, and C.Y. Wang Induction of renal 20-hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats J Pharmacol Exp Ther 317 2006 11 18
19. K. Fukuda, G.H. Tesch, F.Y. Yap, J.M. Forbes, R.A. Flavell, and R.J. Davis MKK3 signalling plays an essential role in leukocyte-mediated pancreatic injury in the multiple low-dose streptozotocin model Lab Invest 88 2008 398 407 (Pubitemid 351432770)
20. A. Müller, P. Schott-Ohly, C. Dohle, and H. Gleichmann Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin Immunobiology 205 2002 35 50 (Pubitemid 34285406)
21. J.C. Henquin Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues Diabetes 53 2004 S48 S58
22. N. Chiamvimonvat, C.M. Ho, H.J. Tsai, and B.D. Hammock The soluble epoxide hydrolase as a pharmaceutical target for hypertension J Cardiovasc Pharmacol 50 2007 225 237 (Pubitemid 47428969)
23. A.A. Elmarakby, J. Faulkner, M. Al-Shabrawey, M.H. Wang, K.R. Maddipati, and J.D. Imig Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes Am J Physiol 301 2011 R1307 R1317
24. C. Morisseau Role of epoxide hydrolases in lipid metabolism Biochimie 95 2013 91 95
25. K. Wagner, B. Inceoglu, and B.D. Hammock Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception Prostaglandins Other Lipid Mediat 96 2011 76 83
26. A.N. Simpkins, R.D. Rudic, D.A. Schreihofer, S. Roy, M. Manhiani, and H.J. Tsai Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection Am J Pathol 174 2009 2086 2095
27. R.J. Roman P450 metabolites of arachidonic acid in the control of cardiovascular function Physiol Rev 82 2002 131 185 (Pubitemid 34654217)
28. H. Huang, C. Morisseau, J. Wang, T. Yang, J.R. Falck, and B.D. Hammock Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats Am J Physiol 293 2007 F342 F349 (Pubitemid 47345035)
29. K. Ohtoshi, H. Kaneto, K. Node, Y. Nakamura, T. Shiraiwa, and M. Matsuhisa Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients Biochem Biophys Res Commun 331 2005 347 350 (Pubitemid 40545182)
30. D. Chen, R. Whitcomb, E. MacIntyre, V. Tran, Z.N. Do, and J. Sabry Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects J Clin Pharmacol 52 2012 319 328
31. J.Y. Liu, S.H. Park, C. Morisseau, S.H. Hwang, B.D. Hammock, and R.H. Weiss Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo Mol Cancer Ther 8 2009 2193 2203